Antifungal prophylaxis for patients with haematological malignancies in ‘real life’: a prospective cohort study of compliance , toxicity and outcome

Ref ID: 17789

Author:

E. Giannatou1,4 , J. Cleverley2 , C. Symeonidou2 , A. Prentice3 , C.C.Kibbler1,4

Author address:

1.Department of Medical Microbiology 2. Department of Radiology 3. Department of Haematology Royal Free Hospital London UK
4.Centre for Clinical Microbiology, University College London

Full conference title:

22nd European Congress of Clinical Microbiology and Infectious Diseases

Abstract:

The liquid formulation of itraconazole has been shown to maintain tissue penetration with reasonably predictable blood levels and to significantly reduce the incidence of invasive fungal infections, including invasive aspergillosis in high risk patients. It is the first line antifungal prophylaxis (AP) in our institution.
However, itraconazole ’s interactions with a long list of drugs given for the treatment of haematological malignancies , coupled with hepatic toxicity and gastrointestinal intolerance, may lead physicians to use alternative prophylaxis for invasive fungal infections in high risk patients.
This prospective cohort study assesses in ’real life’ the compliance with our institution’s antifungal prophylaxis (AP) strategy for patients with haematological malignancies and the reasons for protocol deviation

Abstract Number: P869

Conference Poster: y

Conference Year: 2012

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster